First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 220 participants.
Also called NCT05939076
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 220 participants
- Sponsor
- Registry
-
NCT05939076
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Hungary, Slovakia, Sweden, United Kingdom
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT05939076. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-21 (anticipated); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation
- Condition
- Atrial Fibrillation, Persistent
- Intervention (Device)
- Pulmonary vein isolation
- Intervention (Drug)
- dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
- Lead sponsor
- Region Örebro County
- Collaborator
- The Swedish Research Council
- Collaborator
- Erling-Persson Stiftelse
- Collaborator
- Swedish Heart Lung Foundation
- Collaborator
- Uppsala University
Record details
- Record id
cardio:ct-nct05939076- Content hash
daeb120330f375def8370edf73062dce05f9b128b057dc21f38a0cf35ede5dc8